NCT03526432

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

A Phase II, Single Arm Study of Atezolizumab + Bevacizumab in Women With Advanced, Recurrent or Persistent Endometrial Cancer

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 110 (estimated)
• Sponsor: University of Oklahoma · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm, Phase II study using the combination of atezolizumab and bevicacizumab in women with advanced, recurrent or persistent endometrial cancer. Safety and futility of this drug combination will be assessed to see what effect this treatment has on this patient population.

Detailed description

This phase 2 study using atezolizumab and bevacizumab aims to study the objective tumor response in women with recurrent endometrial cancer. Drugs will be administered via IV every 21 days until disease progression, unacceptable toxicity, or loss of clinical benefit as determined by investigator. Subjects will receive routine cancer care as well as tests and procedures required for the purposes of this study. It is expected this combination will be produce an anti-cancer effect with manageable toxicities in this patient population.

Conditions

• Endometrial Cancer

Interventions

Type	Name	Description
DRUG	Bevacizumab	Bevacizumab will be administered by IV infusion at 15mg/kg on Day 1 of every 21-days cycle.
DRUG	Atezolizumab	Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, loss of clinical benefit as determined by the investigator.

Timeline

• Start date: 2018-08-08
• Primary completion: 2026-03-31
• Completion: 2026-09-01
• First posted: 2018-05-16
• Last updated: 2025-10-24

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study